Catheter Precision Secures First Purchase Order for LockeT from HCA Healthcare Facility

Catheter Precision, Inc. (NYSE American: VTAK), a prominent MedTech company noted for its cardiac electrophysiology products like VIVO™ and LockeT, has announced receiving its first purchase order for LockeT from an HCA Healthcare facility. HCA Healthcare, generating over $64 Billion in 2023, ranks among the top U.S. healthcare service providers, with a vast network of 186 hospitals across 20 states and the United Kingdom.

CEO David Jenkins expressed optimism about this development, highlighting the significance of LockeT's acceptance within HCA's regional medical centers. He indicated potential yearly usage of 1,000 devices across various specialties. Jenkins anticipates this initial purchase might lead to broader adoption among esteemed hospital groups, including teaching institutions, reflecting confidence in the value and effectiveness of their product.